Fujifilm pivots to drugs as printing fades — Panjiva


Fujifilm pivots to drugs as printing fades

Info Tech - Tech Hardware 739 Materials - Chemicals 207 U.S. 5260

Fujifilm has announced a pivot to contract drug making, likely looking to build on its success in finding that its drug Avigan had potential to treat COVID-19. The company is likely anticipating the further fall of photography and printing products, especially as trends around remote working keep many office grade printers and copiers silent. U.S. imports associated with the company fell by 77.5% year over year in October, likely impacted by supply chain pressures on top of the change in strategy. Panjiva analysis of product data shows that the companies imports of chemicals performed m...

Copyright © 2022 Panjiva Supply Chain Intelligence, a product offering from S&P Global Market Intelligence Inc. All rights reserved.